VisCardia aims to change today’s heart failure treatment paradigm with its novel therapy for patients with reduced ejection fraction and preserved ventricular synchrony.
We have concluded our initial clinical studies in Europe. Please look for the results at the major cardiology scientific meetings such as ESC, HFSA, ACC, and AHA.